High-resolution analysis of acquired genomic imbalances in bone marrow samples from chronic myeloid leukemia patients by use of multiple short DNA probes

被引:11
作者
Reid, AG
Tarpey, PS
Nacheva, EP
机构
[1] UCL, Royal Free & Univ Coll Sch Med, Dept Acad Haematol, London NW3 2PF, England
[2] Addenbrookes Hosp, Dept Mol Genet, Cambridge, England
关键词
D O I
10.1002/gcc.10215
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic myeloid leukemia (CML) is a biphasic hematopoietic malignancy associated with a single cytogenetic aberration, the Philadelphia translocation t(9;22)(q34;q11), resulting in the BCR-ABLI fusion oncogene. Molecular heterogeneity was recently demonstrated in the form of extensive deletion of chromosomes 9 and 22 material from the der(9)t(9;22) in 15% of CML patients. The deletions were associated with a worse disease prognosis. Further genetic heterogeneity is seen during the terminal blast crisis stage of CML, in the form of additional non-random chromosome abnormalities. These include most frequently an extra copy of the Ph chromosome, trisomy 8, and isochromosome 17q. We used the genetic heterogeneity of CML as a framework to explore a new technique for high-throughput assessment of locus copy number in malignancy. Multiplex amplifiable probe hybridization (MAPH) relies on the ability of numerous short (100-300 bp) DNA probes to be recovered quantitatively by use of a common primer pair after hybridization to genomic DNA. Derivative chromosome 9 deletions were successfully mapped in a CML cell line (MC3) and nine patient bone marrow samples by simultaneous hybridization of 10 MAPH probes. All results were confirmed by fluorescence in situ hybridization. MAPH was found to be informative in the presence of up to 50% of normal cells, thus establishing the sensitivity of the technique in clonal tumor cell populations. MAPH was performed effectively on DNA samples extracted from fresh or methanol/acetic acid-fixed clonal cell populations. Amplifications of BCR-ABLI were also detected and quantified in four CML cell lines by use of MAPH probes specific for ABL1 exon 11 and BCR exon 1. Our results demonstrate that MAPH is a reproducible high-throughput method suitable for the assessment of genomic imbalances of multiple loci in tumor DNA samples with heterogeneous cell populations at a resolution of 100-300 bp. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:282 / 290
页数:9
相关论文
共 29 条
[1]   Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene [J].
Albertson, DG ;
Ylstra, B ;
Segraves, R ;
Collins, C ;
Dairkee, SH ;
Kowbel, D ;
Kuo, WL ;
Gray, JW ;
Pinkel, D .
NATURE GENETICS, 2000, 25 (02) :144-146
[2]   Measurement of locus copy number by hybridisation with amplifiable probes [J].
Armour, JAL ;
Sismani, C ;
Patsalis, PC ;
Cross, G .
NUCLEIC ACIDS RESEARCH, 2000, 28 (02) :605-609
[3]   TRANSLOCATION OF C-ABL ONCOGENE CORRELATES WITH THE PRESENCE OF A PHILADELPHIA-CHROMOSOME IN CHRONIC MYELOCYTIC-LEUKEMIA [J].
BARTRAM, CR ;
DEKLEIN, A ;
HAGEMEIJER, A ;
VANAGTHOVEN, T ;
VANKESSEL, AG ;
BOOTSMA, D ;
GROSVELD, G ;
FERGUSONSMITH, MA ;
DAVIES, T ;
STONE, M ;
HEISTERKAMP, N ;
STEPHENSON, JR ;
GROFFEN, J .
NATURE, 1983, 306 (5940) :277-280
[4]   Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes [J].
Bench, AJ ;
Nacheva, EP ;
Hood, TL ;
Holden, JL ;
French, L ;
Swanton, S ;
Champion, KM ;
Li, J ;
Whittaker, P ;
Stavrides, G ;
Hunt, AR ;
Huntly, BJP ;
Campbell, LJ ;
Bentley, DR ;
Deloukas, P ;
Green, AR .
ONCOGENE, 2000, 19 (34) :3902-3913
[5]   The molecular biology of chronic myeloid leukemia [J].
Deininger, MWN ;
Goldman, JM ;
Melo, JV .
BLOOD, 2000, 96 (10) :3343-3356
[6]   LOCATION OF BREAKPOINTS WITHIN THE MAJOR BREAKPOINT CLUSTER REGION (BCR) IN 33 PATIENTS WITH BCR REARRANGEMENT-POSITIVE CHRONIC MYELOID-LEUKEMIA (CML) WITH COMPLEX OR ABSENT PHILADELPHIA CHROMOSOMES [J].
DUBE, I ;
DIXON, J ;
BECKETT, T ;
GROSSMAN, A ;
WEINSTEIN, M ;
BENN, P ;
MCKEITHAN, T ;
NORMAN, C ;
PINKERTON, P .
GENES CHROMOSOMES & CANCER, 1989, 1 (01) :106-111
[7]   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].
Gorre, ME ;
Mohammed, M ;
Ellwood, K ;
Hsu, N ;
Paquette, R ;
Rao, PN ;
Sawyers, CL .
SCIENCE, 2001, 293 (5531) :876-880
[8]   Comparative analysis of G-banding, chromosome painting, locus-specific fluorescence in situ hybridization, and comparative genomic hybridization in chronic myeloid leukemia blast crisis [J].
Gribble, SM ;
Sinclair, PB ;
Grace, C ;
Green, AR ;
Nacheva, EP .
CANCER GENETICS AND CYTOGENETICS, 1999, 111 (01) :7-17
[9]   Cytogenetics of the chronic myeloid leukemia-derived cell line K562: Karyotype clarification by multicolor fluorescence in situ hybridization, comparative genomic hybridization, and locus-specific fluorescence in situ hybridization [J].
Gribble, SM ;
Roberts, I ;
Grace, C ;
Andrews, KM ;
Green, AR ;
Nacheva, EP .
CANCER GENETICS AND CYTOGENETICS, 2000, 118 (01) :1-8
[10]   PHILADELPHIA CHROMOSOMAL BREAKPOINTS ARE CLUSTERED WITHIN A LIMITED REGION, BCR, ON CHROMOSOME-22 [J].
GROFFEN, J ;
STEPHENSON, JR ;
HEISTERKAMP, N ;
DEKLEIN, A ;
BARTRAM, CR ;
GROSVELD, G .
CELL, 1984, 36 (01) :93-99